sellWeak cluster of 310b5-1 plan
Jeffrey W. Albers sold $1.3M of BPMC
director at Blueprint Medicines Corp. 15,000 shares at an average of $89.77, traded Dec 19, 2024, filed Dec 20, 2024.
Warning score
20Value
$1.3M
15,000 shares
Holdings after
157,557
-9% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$1.3M at market
- 0Share of holdings soldSold 8.7% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-029971, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2024 | MOption exercise Common Stock10b5-1 | +15,000 | $36.05 | $541k | 172,557 | Dec 20, 2024 |
| Dec 19, 2024 | SOpen-market sale Common Stock10b5-1 | -3,920 | $88.28 | $346k | 168,637 | Dec 20, 2024 |
| Dec 19, 2024 | SOpen-market sale Common Stock10b5-1 | -5,180 | $89.01 | $461k | 163,457 | Dec 20, 2024 |
| Dec 19, 2024 | SOpen-market sale Common Stock10b5-1 | -3,800 | $91.15 | $346k | 159,657 | Dec 20, 2024 |
| Dec 19, 2024 | SOpen-market sale Common Stock10b5-1 | -2,100 | $91.96 | $193k | 157,557 | Dec 20, 2024 |
| Dec 19, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $36.05 | $541k | 120,000 | Dec 20, 2024 |
Related signals
Other insiders at Blueprint Medicines Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | Blueprint Medicines Corp | Percy H. Carter CHIEF SCIENTIFIC OFFICER | $135k 1,051 shares | -2% | |
| 39Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $150k 1,172 shares | -2% | |
| 38Weak | Blueprint Medicines Corp | Percy H. Carter CHIEF SCIENTIFIC OFFICER | $340k 2,659 shares | -5% | |
| 13Weak | Blueprint Medicines Corp | Jeffrey W. Albers director | $506k 5,000 shares | -3% | |
| 28Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $229k 2,274 shares | -3% | |
| 7Weak | Blueprint Medicines Corp | Ariel Hurley PRINCIPAL ACCOUNTING OFFICER | $284k 2,752 shares | -14% | |
| 21Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $231k 2,274 shares | -3% | |
| 25Weak | Blueprint Medicines Corp | Kate Haviland CHIEF EXECUTIVE OFFICER | $216k 2,498 shares | -1% | |
| 27Weak | Blueprint Medicines Corp | Christina Rossi CHIEF OPERATING OFFICER | $216k 2,274 shares | -3% | |
| 48Moderate | Blueprint Medicines Corp | Jeffrey W. Albers director | $512k 5,766 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.